1 |
식품의약품안전청. 의약품임상시험관리기준, 2001.
|
2 |
Office of Inspector General, U.S. Department of Health and Human Services. Institutional Review Boards: A time for reform, 1998.
|
3 |
Maschke KJ. Human research protection: Time for regulatory reform. Hastings Center Report, 2008;38(2):19-22.
DOI
|
4 |
Kim OJ, Park BJ, Sohn DR, Lee SM, Shin SG. Current status of the Institutional Review Boards in Korea: constitution, operation, and policy for protection of human research participants. J Korean Med Sci, 2003;18(1):3-10.
DOI
|
5 |
Weijer C, Shapiro SH, Fuks A, Glass KC, S krutkowska M. Monitoring clinical research: An obligation unfulfilled. Can Med Assoc J , 1995;152(12):1973-1979.
|
6 |
Food and Drug Administration. Guidance for clinical investigators, sponsors, and IRBs adverse event reporting to IRBs-improving human subject protection http://www.fda.gov/ downloa ds/RegulatoryInformation/Guidances/ UCM126572.pdf [Online] (last visited on 28 Feb 2011)
|
7 |
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. E6 Guideline for Good Clinical Practice, 1996.
|
8 |
Dunn CM, Chadwick GL. Protecting study volunteers in research. 3rd ed. Thomson CenterWatch, Boston, MA, 2004;13-27.
|
9 |
Beecher HK. Ethics and clinical research. N Engl J Med, 1966;274(24):1354-1360.
DOI
ScienceOn
|
10 |
The World Medical Association. Declaration of Helsinki (1st ed.), 1964.
|
11 |
Park BJ. The suggestions for improving the operation of Institutional Review Boards. Kor J Clin Pharmacol Ther, 2002;10(1):83-86. (Korean)
|